Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Simcere Pharmaceutical, a pharmaceutical company engaged in manufacturing, developing and marketing branded and proprietary pharmaceuticals in China, has reported total revenue of RMB587.73m ($89.05m) for the fourth quarter ended 31 December 2010, an increase of 7.6% as compared to the total revenue of RMB546.45m for the same period in 2009.
Subscribe to our email newsletter
Simcere Pharma has posted a net loss of RMB58.7m ($8.89m) for the fourth quarter of 2010, compared to a loss of RMB75.42m for the same period in 2009.
The company’s loss from operations was RMB62.82m ($9.52m), compared to RMB 25,77m for the same period in 2009.
For the full-year ended 31 December 2010, the company has reported net income of RMB172.41m ($26.12m), which represented an increase of 552.4% from RMB 26.43m for the same period in 2009.
Total revenues for the full-year of 2010 were RMB2,141.1m ($324.41m),, compared to RMB1,857.07m for the same period in 2009.
Simcere Pharma chairman and CEO Jinsheng Ren said during the fourth quarter, Simcere’s revenue and net income continued the stable growth trend of the previous three quarters, and they were especially encouraged by Endu’s sales performance.
"Highlighting the success of Simcere’s R&D efforts, during the year, we filed four clinical trial applications with the SFDA," Ren said.